이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

작게 태어난 아이들과 작게 태어난 아이들에 대한 연구. 치료는 하루에 한 번 Norditropin®에 비해 일주일에 한 번 소마파시탄입니다.

2026년 10월 5일 업데이트: Novo Nordisk A/S

2세 이상까지 따라잡기 성장이 없는 재태 주령에 비해 작게 태어난 저신장 소아에서 매일 Norditropin®과 비교하여 Somapacitan 주 1회 치료의 효과 및 안전성을 평가하는 용량 결정 시험

The study compares 2 medicines used for the treatment of children who are born small and who stayed small: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe).

Participants will either get somapacitan or Norditropin® - which treatment is decided by chance. Both participants and the study doctor will know which treatment the participants get. The study will last for 5 years. Participants will take either an injection once every week or once every day.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

62

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Bergen, 노르웨이, 5021
        • Haukeland Universitetssykehus, Barneklinikken
      • Copenhagen Ø, 덴마크, 2100
        • Rigshospitalet Klinik for Vækst og Reproduktion Afsnit 5064
      • Riga, 라트비아, 1004
        • Children's Clinical University Hospital
      • Izhevsk, 러시아 제국, 426009
        • Republic Children's Hospital of Ministry of Health of Udmurt
      • Moscow, 러시아 제국, 119435
        • Setchenov First Moscow State Medical University
      • Moscow, 러시아 제국, 125373
        • RMAPE
      • Novosibirsk, 러시아 제국, 630048
        • Children's clinical city hospital #1
      • Rostov-on-Don, 러시아 제국, 344013
        • FSBEI of Higher Education "Rostov State Medical University"
      • Saint Petersburg, 러시아 제국, 191144
        • SPSBHI City Children out-patient clinic #44
      • Samara, 러시아 제국, 443079
        • Samara Regional Children Clinical Hospital n.a. N.N. Ivanova
      • Tomsk, 러시아 제국, 634050
        • Siberian State Medical University
    • Alabama
      • Birmingham, Alabama, 미국, 35233
        • Univ of AL at Birmingham_BRM
    • California
      • Orange, California, 미국, 92868
        • Children's Hosp Of Orange
    • Idaho
      • Boise, Idaho, 미국, 83712
        • St. Luke's Children's Endo
    • Minnesota
      • Minneapolis, Minnesota, 미국, 55454
        • Univ of Minnesota M.C.H.
      • Saint Paul, Minnesota, 미국, 55102
        • Children's Minnesota
    • New Jersey
      • Morristown, New Jersey, 미국, 07962
        • Goryeb Children's Hospital
      • New Brunswick, New Jersey, 미국, 08901
        • Rutgers-Rwjms
    • New York
      • Garden City, New York, 미국, 11530
        • NYU Langone Hospital-LI
      • Mineola, New York, 미국, 11501
        • NYU Langone Hospital-LI
      • New York, New York, 미국, 10029
        • Icahn Sch of Med-Mt Sinai Hosp
    • Ohio
      • Cincinnati, Ohio, 미국, 45229
        • CCHMC_Cinc
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • Univ Oklahoma Sci Ctr OK City
    • Texas
      • Fort Worth, Texas, 미국, 76104
        • Cook Children's Hospital-Hematology-Oncology
    • Washington
      • Tacoma, Washington, 미국, 98405
        • MultiCare Inst for Res & Innov
      • Belgrade, 세르비아, 11000
        • University Children's Hospital Tirsova
      • Belgrade, 세르비아, 11070
        • Institute for Mother and Child Health Care of Serbia
      • Kragujevac, 세르비아, 34000
        • University Clinical Centre Kragujevac
      • Niš, 세르비아, 18 000
        • Clinical Center in Nis
      • Novi Sad, 세르비아, 21000
        • Institute for Health Care of Children and Adolescents
      • Bern, 스위스, 3010
        • Med. Kinder- und Poliklinik
      • Zurich, 스위스, 8032
        • Kinderspital Endokrinologie, Zürich
      • Esplugues Llobregat(Barcelona), 스페인, 08950
        • Hospital Sant Joan de Déu
      • Santiago de Compostela, 스페인, 15706
        • Hospital Clínico de Santiago de Compostela
      • Dublin, 아일랜드, D12 N512
        • CHI Crumlin Dept of Endocrinology
      • Algiers, 알제리, 16000
        • CHU Bab El Oued Pediatrics Dept
      • Algiers, 알제리, 16000
        • Endo and Diab Dept El Oued
      • Constantine, 알제리, 25000
        • endocrino-diabetology department, Hospital IBN BADIS.
      • Tallinn, 에스토니아, 13419
        • Tallinn Children's Hospital
      • Tartu, 에스토니아, 50406
        • Tartu University Hospital Children's Clinic
      • Hull, 영국, HU3 2JZ
        • Hull Royal Infirmary
      • Liverpool, 영국, L12 2AP
        • Alder Hey Children's Hospital
      • London, 영국, E1 1BB
        • Royal London Hospital_London
      • Manchester, 영국, M13 9WL
        • Royal Manchester Children's Hospital
      • Graz, 오스트리아, 8036
        • Med. Univ. Graz -Klinische Abteilung f. Allgemeine Pädiatrie
      • Salzburg, 오스트리아, A 5020
        • LKH Salzburg- Univ. Klinik f. Kinder- und Jugendheilkunde
      • Sankt Pölten, 오스트리아, 3100
        • LKH St. Poelten, Kinder-und Jugendheilkunde
      • Vöcklabruck, 오스트리아, 4840
        • Salzkammergut-Klinikum Vöcklabruck
    • Upper Austria
      • Linz, Upper Austria, 오스트리아, 4020
        • Kepler Universitätsklinikum GmbH - Med Campus IV (vorm.LFKK)
      • Dnipro, 우크라이나, 49100
        • Dnipropetrovsk Regional Children's Clinical Hospital - Endocrinology department
      • Kharkiv, 우크라이나, 61093
        • Kharkiv Regional Children's Clinical Hospital - Endocrinological department
      • Kyiv, 우크라이나, 04114
        • Komisarenko Institute of Endocrinology and Metabolism of NAMSU - Department of paediatric endocrine pathology
      • Haifa, 이스라엘, 31096
        • Rambam MC - Department of Pediatrics A
      • Kfar Saba, 이스라엘, 44281
        • Meir MC - Department of Paediatrics
      • Petah Tikva, 이스라엘, 49202
        • Schneider MC - Endrocrinology and Diabetes
      • Florence, 이탈리아, 50139
        • IRCCS Meyer Firenze
      • Genova, 이탈리아, 16147
        • Ospedale Pediatrico Gaslini
      • Milan, 이탈리아, 20122
        • Ospedale Maggiore Policlinico UO Endocrinologia Diabetolgia
      • Roma, 이탈리아, 00165
        • Ospedale Pediatrico Bambino Gesu
    • Kerala
      • Kochi, Kerala, 인도, 682041
        • Amrita Institute Of Medical Sciences & Research Centre
    • Maharashtra
      • Pune, Maharashtra, 인도, 411001
        • Jehangir Clinical Development Centre
    • New Delhi
      • New Dehli, New Delhi, 인도, 110029
        • All India Institute of Medical Sciences
      • Fukuoka, 일본, 830-0011
        • Kurume University Hospital, Pediatrics
      • Fukuoka-shi, Fukuoka, 일본, 813-0017
        • Fukuoka Children's Hospital_Endocrinology and Metabolism
      • Fukuoka-shi, Fukuoka, 일본, 813-0017
        • Fukuoka Children's Hospital
      • Fukuyama-shi, Hiroshima, 일본, 721-8511
        • Fukuyama City Hospital_Department of Pediatrics
      • Kobe-shi, Hyogo, 일본, 650-0047
        • Hyogo Prefectual Kobe Children's Hospital Dept. Metab & endo
      • Kobe-shi, Hyogo, 일본, 650-0047
        • Hyogo Prefectual Kobe Children's Hospital_Metab & endo
      • Kyoto, 일본, 602-8566
        • Univ.HP, Kyoto Pref Univ of Medicine, Dept. of Pediatrics
      • Nara-shi, Nara, 일본, 630-8581
        • Nara Prefecture General Medical Center_ Nara-shi, Nara
      • Nara-shi, Nara, 일본, 630-8581
        • Nara Prefecture General Medical Center_Pediatric
      • Niigata-shi, Niigata, 일본, 951 8520
        • Niigata University Medical & Dental Hospital_Pediatrics
      • Osaka, 일본, 534-0021
        • Osaka City General Hospital, Pediatric Endocrinology and Me
      • Osaka, 일본, 594-1101
        • Osaka Women's and Children's Hospital
      • Saitama-shi, Saitama, 일본, 330-8777
        • Saitama Children's Medical Center, Endocrinorogy&Metabolism
      • Tokyo, 일본, 157 8535
        • National Center for Child Health and Dev, Endo and Metabo
      • Tokyo, 일본, 113-8519
        • Institute of Science Tokyo Hospital
      • Tokyo, 일본, 113-8519
        • Institute of Science Tokyo Hospital_Pediatrics
      • Tokyo, 일본, 157 8535
        • National Center for Child Health and Development_Endo and Metabo
      • Tokyo, 일본, 160-8582
        • Keio University Hospital_Pediatrics
    • Alberta
      • Edmonton, Alberta, 캐나다, T6G 2B7
        • Stollery Children's Hospital
      • Bangkok, 태국, 10330
        • King Chulalongkorn Memorial hospital-Ped-Endocrinology
      • Bangkok, 태국, 10330
        • King Chulalongkorn Memorial hospital_Ped-Endocrinology
      • Bangkok, 태국, 10400
        • Phramongkutklao Hospital_Ped-Endo_Pediatrics
      • Szczecin, 폴란드, 71-252
        • SPSK nr 1 im Prof. T Sokolowskiego
      • Warsaw, 폴란드, 04-730
        • Instytut ''Pomnik - Centrum Zdrowia Dziecka''
      • Angers, 프랑스, 49100
        • Centre Hospitalier Universitaire D'Angers-2
      • Le Kremlin-Bicêtre, 프랑스, 94270
        • AP-HP-HOPITAL DE BICETRE_Service d'Endocrinologie pédiatrique
      • Marseille, 프랑스, 13005
        • Assistance Publique Hopitaux de Marseille-Hopital de La Timone-2
      • Marseille Cédex 05, 프랑스, 13385
        • Hopital de La Timone
      • Paris, 프랑스, 75015
        • Ap-Hp-Hopital Necker
      • Paris, 프랑스, 75015
        • Hôpital Necker
      • Toulouse, 프랑스, 31059
        • HOPITAL DES ENFANTS-HOPITAL PAULE DE VIGUIER - Pharmacie
      • Budapest, 헝가리, 1023
        • Észak-Közép-budai Centrum, Szent János Kórház és Szakrendelő
      • Szeged, 헝가리, 6720
        • Szegedi Tudományegyetem Gyermekgyógyászati Klinika

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

2년 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Pre-pubertal children, boys:

    1. age between 2.5 and 11.0 years at screening.
    2. testes volume below 4 ml.
  • Pre-pubertal children, girls:

    1. age between 2.5 and 10.0 years at screening.
    2. Tanner stage 1 for breast development (no palpable glandular breast tissue).
  • Born small for gestational age (birth length and/or weight below -2 standard deviation scores) (according to national standards).

  • Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and gender at screening according to the standards of Centers for Disease Control and Prevention at screening.

  • Impaired height velocity defined as annualized height velocity below the 50th percentile for chronological age and gender according to the standards of Prader calculated over a time span of minimum 6 months and maximum 18 months prior to screening.

  • No prior exposure to growth hormone therapy or Insulin-like Growth Factor-I (IGF-I) treatment.

Exclusion Criteria:

  • Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with standing height measurements.
  • Children with hormonal deficiencies including suspected or confirmed growth hormone deficiency according to local practise.
  • Current inflammatory diseases requiring systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening.
  • Children requiring inhaled glucocorticoid therapy at a dose of greater than 400 μg/day of inhaled budesonide or equivalents for longer than 4 consecutive weeks within the last 12 months prior to screening.
  • Concomitant administration of other treatments that may have an effect on growth, e.g but not limited to methylphenidate for treatment of attention deficit hyperactivity disorder.
  • Diagnosis of attention deficit hyperactivity disorder.
  • Prior history or presence of malignancy including intracranial tumours.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Somapacitan 0.24 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

실험적: Somapacitan 0.20 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

실험적: Somapacitan 0.16 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

활성 비교기: Norditropin® 0.035 mg/kg/day

Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Norditropin® injected under the skin once a day.

활성 비교기: Norditropin® 0.067 mg/kg/day

Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Norditropin® injected under the skin once a day.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Height Velocity
기간: Baseline (week 0); week 26

Height velocity (HV) was derived from height measurements taken at baseline (week 0) and week 26 visit as: HV = (height at 26 weeks visit - height at baseline)/(time from baseline to 26 weeks visit in years). The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26

2차 결과 측정

결과 측정
측정값 설명
기간
Change in Ratio of Bone Age Versus Chronological Age
기간: Baseline (week 0); week 52

Change in ratio of bone age (years) versus chronological age (years) from baseline (week 0) to week 52 is presented. X-rays of left hand and wrist for bone age assessment according to the Greulich and Pyle atlas were taken. X-ray images were sent to a central imaging laboratory for evaluation. Chronological Age (years) was calculated as: (Date minus Date of Birth) divided by 365.25. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 52 or last trial contact, whichever came first.

Baseline (week 0); week 52
Change in Height Standard Deviation Score (HSDS)
기간: Baseline (week 0); week 26

Change in HSDS from baseline (week 0) to week 26 is presented. HSDS was derived using Centre for Disease Control and Prevention (CDC) standards. HSDS = [(height/population median)^skewness - 1]/(skewness * population standard deviation) where skewness, median and standard deviation is given by a reference growth table for the corresponding chronological age. The range for HSDS was -10 to +10. Negative scores indicated a height below the mean height for a child with the same age and gender, whereas positive scores indicated a height above the mean height for a child with the same age and gender. Positive value in change from baseline in HSDS indicated that HSDS was better than baseline HSDS In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26
Change in Height Velocity Standard Deviation Score (HVSDS)
기간: Baseline (week 0); week 26

Change in HVSDS from baseline (week 0) to week 26 is presented. HVSDS was derived using Prader standards. HV SDS was calculated using the formula: HV SDS = (height velocity - mean)/standard deviation (SD), where height velocity was the height velocity variable measured, mean and SD of height velocity by gender and age for the reference population. The range for HVSDS was -10 to +10. Negative scores indicated a height velocity below the mean height velocity for a child with the same age and gender, whereas positive scores indicated a height velocity above the mean height velocity for a child with the same age and gender. Positive value in change from baseline in HVSDS indicated that HVSDS was better than baseline HVSDS. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26
Change in Fasting Plasma Glucose
기간: Baseline (week 0); week 26

Change in fasting plasma glucose from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Homeostatic Model Assessment for Steady State Beta Cell Function (HOMA-B)
기간: Baseline (week 0); week 26

Change in HOMA-B from baseline (week 0) to week 26 is presented. HOMA-B is a measure of the beta cell function and was calculated as follows: HOMA-B = (20 * fasting insulin (picomoles per liter [pmol/L]) * 1/6(microunit per milliliter [µU/mL]))/ FPG(mmol/L)-3.5). HOMA-beta score ranges from minus infinity to infinity (no limits). Higher score means better beta-cell function for HOMA-beta. Negative change from baseline (week 0) in HOMA-B indicated a worse outcome. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
기간: Baseline (week 0); week 26

Change in HOMA-IR from baseline (week 0) to week 26 is presented. Insulin resistance is a condition in which cells fail to respond to normal actions of hormone in body. HOMA-IR is calculated using a participant's fasting plasma insulin and glucose levels. HOMA-IR = fasting serum insulin (micro international units per milliliter (μU/ml)) × fasting plasma glucose (millimoles per liter (mmol/l)) / 22.5. HOMA-IR scores are classified as follows: less than 1.0: considered insulin sensitive, 0.5-1.4: considered healthy, above 1.8: considered early insulin resistance; above 2.7 is considered significant insulin resistance. HOMA-IR score ranges from 0-infinity (no upper limit). Higher the score, higher the level of insulin resistance. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Glycated Haemoglobin (HbA1c)
기간: Baseline (week 0); week 26

Change in HbA1c from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Insulin-like Growth Factor I (IGF-I) Standard Deviation Score (SDS)
기간: Baseline (week 0); week 26

Change in IGF-I SDS from baseline (week 0) to week 26 is presented. IGF-I SDS was provided by the central laboratory; its calculation is based on the actual value of IGF-1 minus mean reference value of IGF-1 divided by reference standard deviation of IGF-1. The range for IGF-I SDS was from -10 to +10. Negative scores indicated a IGF-I below the mean IGF-I for a child with the same age and gender, whereas positive scores indicated a IGF-I above the mean IGF-I for a child with the same age and gender. Positive value in change from baseline in IGF-I SDS indicated that IGF-I SDS was higher than baseline IGF-I SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) SDS
기간: Baseline (week 0); week 26

Change in IGFBP-3 SDS from baseline (week 0) to week 26 is presented. The range for IGFBP-3 SDS was from -10 to +10. Negative scores indicated a IGFBP-3 below the mean IGFBP-3 for a child with the same age and gender, whereas positive scores indicated a IGFBP-3 above the mean IGFBP-3 for a child with the same age and gender. Positive value in change from baseline in IGFBP-3 SDS indicated that IGFBP-3 SDS was higher than baseline IGFBP-3 SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Clinical Reporting Anchor and Disclosure 1452, Novo Nordisk A/S

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2019년 7월 4일

기본 완료 (실제)

2021년 5월 5일

연구 완료 (추정된)

2026년 12월 23일

연구 등록 날짜

최초 제출

2019년 3월 15일

QC 기준을 충족하는 최초 제출

2019년 3월 15일

처음 게시됨 (실제)

2019년 3월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 5일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • NN8640-4245
  • 2018 (미국 NIH 보조금/계약)
  • U1111-1207-9741 (기타 식별자: World Health Organization (WHO))
  • 2018-000232-10 (EudraCT 번호)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .